Evidence map›Paper›PMID 33830643›Full record

ArticleESC heart failure2021

The potential role of plasma miR-155 and miR-206 as circulatory biomarkers in inflammatory cardiomyopathy.

Danilo Obradovic, Karl-Philipp Rommel, Stephan Blazek, Karin Klingel, Matthias Gutberlet, Christian Lücke, Petra Büttner, Holger Thiele, Volker Adams, Philipp Lurz and 2 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. The Role of MicroRNAs in Myocarditis-What Can We Learn from Clinical Trials?International journal of molecular sciences · 2022
    Review
  14. Article
  15. Review
  16. Exosomal microRNAs in diabetic heart disease.Cardiovascular diabetology · 2022
    Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Danilo ObradovicDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-2890-5755
Karl-Philipp RommelDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-2901-8138
Stephan BlazekDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.
Karin KlingelCardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0003-0203-2498
Matthias GutberletDepartment of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany.ORCID 0000-0003-4879-0438
Christian LückeDepartment of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany.ORCID 0000-0002-0443-977X
Petra BüttnerDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0003-0799-4725
Holger ThieleDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-0169-998X
Volker AdamsLaboratory of Molecular and Experimental Cardiology, Heart Center Dresden, Technical University Dresden, Dresden, Germany.ORCID 0000-0002-7955-7324
Philipp LurzDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-5993-4487
Fabian EmrichDepartment of Cardiothoracic Surgery, University Hospital Frankfurt, Frankfurt, Germany.ORCID 0000-0003-4546-889X
Christian BeslerDepartment of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Strümpellstraße 39, Leipzig, 04289, Germany.ORCID 0000-0002-8082-6472
Leipzig Heart Institute · DEGoethe University Frankfurt · DETechnische Universität Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsEstablishing a diagnosis of inflammatory cardiomyopathy (iCMP) by non-invasive means remains challenging despite advances in cardiac magnetic resonance imaging. Previous studies suggested the involvement of microRNAs in the pathogenesis of iCMP. We examined the association of a predefined set of circulatory microRNAs with clinical characteristics of iCMP and evaluated their diagnostic performance in suspected iCMP. METHODS AND

resultsEighty-nine patients with clinical suspicion of iCMP were included in the analysis. All patients underwent cardiac catheterization with left ventricular endomyocardial biopsy, echocardiography, and cardiac magnetic resonance imaging applying the Lake Louise criteria (LLC). Plasma levels of miR-21, miR-126, miR-133a, miR-146b, miR-155, and miR-206 were determined using real-time polymerase chain reaction. Based on immunohistological findings on endomyocardial biopsy, iCMP was diagnosed in 67% of study participants (n = 60). Plasma levels of miR-155 and miR-206 were significantly increased in patients with iCMP as compared with patients with dilated cardiomyopathy (P = 0.008 and P = 0.009, respectively). In receiver operating characteristic curve analysis, miR-155 and miR-206 demonstrated superior diagnostic performance for iCMP (0.68 and 0.67, respectively) compared with LLC [area under the curve (AUC) 0.60], Troponin T (AUC 0.51), and N-terminal pro-brain natriuretic peptide (AUC 0.51). While baseline miR-155 and miR-206 plasma levels were predictive for biopsy-proven iCMP (odds ratio = 2.61, 95% confidence interval = 1.28-5.31, P = 0.008 and odds ratio = 2.65, 95% confidence interval = 1.27-5.52, P = 0.009) on univariate logistic regression analysis, the presence of positive LLC, high baseline C-reactive protein, or presence of clinical symptoms and signs of viral infection failed to predict iCMP (P > 0.05, respectively).

conclusionsThe present data suggest that plasma levels of miR-206 and miR-155 are potential novel biomarkers for confirming the diagnosis of iCMP.

Indexed as

Cardiomyopathy, DilatedMicroRNAsMyocarditisBiomarkersHumansMyocardiumBiomarkersMicroRNAsMIRN155 microRNA, humanMIRN206 microRNA, humanCardiovascular magnetic resonance imagingDilated cardiomyopathyEndomyocardial biopsyInflammatory cardiomyopathyLake Louise criteriamiRNA

Identifiers

PMID33830643
PMCPMC8120377
OpenAlexW3148506672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.